Abstract Details

Title Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h Rivastigmine Patch on Activities of Daily Living in Severe Alzheimer's Disease: A Factor Analysis

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) (-)

Poster/Presentation
Number 008

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Drew Velting, PhD (Novartis Pharmaceuticals Corp.)	No disclosure on file
	No disclosure on file
Claudia Kawas, MD (University of California, Irvine)	The institution of Dr. Kawas has received research support from NIH.

�鶹��ýӳ��